Compare S&P Global Inc (SPGI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? S&P Global Inc trades at $433 (market cap $132.71B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: S&P Global Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and S&P Global Inc pays a 0.87% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SPGI | VRTX | |
|---|---|---|
Market Cap | $132.71B | $121.95B |
Sector | Financials | Health |
52-Week High | $534.79 | $529.59 |
52-Week Low | $370.42 | $366.54 |
Enterprise Value | $144.68B | $116.69B |
Dividend Yield | 0.87% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
